Information Pibrentasvir (ABT-530) Pibrentasvir (ABT-530) is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50 ranging from 1.4 pM to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6. Targets GT5a (Cell-free assay); GT1a H77 (Cell-free assay); GT2b (Cell-free assay); GT4a (Cell-free assay); GT3a (Cell-free assay) 33615,1.4 pM(EC50); 1.8 pM(EC50); 1.9 pM(EC50); 1.9 pM(EC50); 2.1 pM(EC50) In vitro Pibrentasvir is a next-generation HCV NS5A inhibitor with potent and pan-genotypic activity, and it maintains activity against common amino acid substitutions of HCV genotypes 1 to 6 that are known to confer resistance to currently approved NS5A inhibitors. Cell Research(from reference) Cell lines：Huh-7 human hepatoma cell line, CEM-SS cells Incubation Time：6 days